UMUYOBOZI W'umuryango

FDA Clinical Decision Support Software Guidance

FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply.

  • 3 min soma
  • Ibiherutse kuvugururwa
Kuriyi page3 min soma
  1. Incamake
  2. Kwibira cyane
  3. Ingaruka z'Ingamba
  4. The Future of FDA Clinical Decision Support Software Guidance
  5. Gushyira mu bikorwa Isi
  6. Ingaruka & Kurinda
  7. Igishushanyo mbonera
  8. Komeza Ubushakashatsi
  9. Ibibazo bikunze kubazwa

Incamake

The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.

Kwibira cyane

Clinical decision support software provides information or recommendations to support healthcare decisions. FDA’s guidance explains how the agency assesses software functions under the applicable statutory criteria. Some functions may be excluded from the device definition when they meet specific conditions, including that a health professional can independently review the basis for recommendations. Other functions, including certain patient-specific analyses or device functions, may remain subject to oversight. The assessment is about what a particular software function does, its intended user, and how the output is used. A product can contain multiple functions with different regulatory status. A tool that presents evidence for a clinician to review is not automatically treated the same as software that directs diagnosis or treatment. FDA guidance also notes that functions intended for patients or caregivers may be assessed differently from clinician-facing support. Manufacturers should define each function and provide information that supports independent review where relevant. Clinicians should understand what inputs and evidence support a recommendation, the intended population, and limitations. A generated explanation is not itself proof of the underlying basis. Check current FDA guidance and product labeling for the specific function. This guide summarizes concepts and does not determine regulatory status for a product. Preserve examples of intended use and evidence that support the analysis, and revisit it when users, claims, or outputs change. Keep patient-facing and clinician-facing functions distinct in requirements and documentation.

Ingaruka z'Ingamba

Ibyago n'umutekano

Catastrophique na burimunsi AI yangiza byombi biterwa nuwumva ingaruka ninde ushobora gukora.

Ibyemezo bisobanutse

Kumenya gusoma no kwandika rusange kandi byumwuga byerekana niba politiki yumutekano ikomeye ishoboka muri politiki.

Gukata binyuze mu gusebanya

Ibisobanuro bisobanutse bigabanya gufatwa ukoresheje impuha, laboratoire PR, hamwe namakinamico adasobanutse.

The Future of FDA Clinical Decision Support Software Guidance

Decision-support products increasingly use machine learning and generative models, creating new questions about explainability and how clinicians review evidence. FDA guidance is updated as laws and technology change. Developers should monitor current agency materials and preserve a function-level analysis. Care teams need training to interpret outputs and should retain clinical judgment even when a tool is authorized. Developers should design interfaces that make the evidence and limitations easy to inspect, not merely generate a plausible explanation. Monitor outcomes and user feedback.

Gushyira mu bikorwa Isi

A clinician reviews sources and rationale behind a recommendation before acting.

A software team separates administrative reminders from patient-specific treatment recommendations.

A hospital confirms whether a function is intended for health professionals or patients.

A developer maps the product’s intended use to the criteria in current FDA guidance.

Ingaruka & Kurinda

  • Gufata ibyago bibaho nka sci-fi mugihe ubushobozi bwimbaraga.

  • Kwitiranya umutekano wibicuruzwa byo hejuru hamwe no guhuza munsi y'ubwigenge buhanitse.

  • Kureka abatari Icyongereza nabatari abahanga bafite isoko yo hasi gusa.

Igishushanyo mbonera

  1. Gutandukanya ibicuruzwa byangiza, gukoresha nabi, no gutakaza-kugenzura / ingaruka mbi.

  2. Baza ibimenyetso byahindura uko ubona ku gihe n'uburemere.

  3. Hitamo inkomoko yibanze nibisobanuro bifatika kubisabwa byo kwamamaza.

  4. Menya inzira imwe y'ibikorwa: umwuga, politiki, inkunga, cyangwa ubuhanga - ntabwo ari ukumenya gusa.

Komeza Ubushakashatsi

Free newsletter

Get the daily AI briefing

Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.

One email each weekday. Unsubscribe in one click. We never sell or share your address.

Test yourself

Take the FDA Clinical Decision Support Software Guidance quiz

Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.

Tangira ikibazo

Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation

Ibibazo bikunze kubazwa

What is FDA Clinical Decision Support Software Guidance?

FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply. The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.

What does FDA evaluate in clinical decision-support software?

Regulatory analysis depends on the function and how it is used.

Why analyze a product function by function?

Regulatory assessment is not necessarily product-wide and uniform.

What should developers document for a function?

Function-specific documentation supports assessment and use.

What should clinicians do with a CDS recommendation?

CDS supports decisions and does not replace professional review.